Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | AGXT | P21549 | 2/20 | 0.55 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 4/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8881644 | 0.87 | TSHR (0.52) | IDO1AGXTLMNATSHRPTGS1 | |
| SCHEMBL502 | 0.87 | TSHR (0.52) | IDO1AGXTLMNATSHRPTGS1 | |
| SCHEMBL7617607 | 0.85 | TSHR (0.50) | IDO1AGXTLMNATSHRPTGS1 | |
| SCHEMBL27597789 | 0.83 | TSHR (0.48) | IDO1AGXTLMNATSHRPTGS1 | |
| SCHEMBL5540731 | 0.82 | AGXT (0.59) | AGXTNAAAFFAR1MGLL | |
| Methyl Alcohol SCHEMBL28296456 | 0.81 | ALDH1A1 (0.50) | IDO1AGXTLMNATSHRPTGS1 | |
| Cyanide SCHEMBL27392144 | 0.81 | TSHR (0.46) | IDO1AGXTLMNATSHRPTGS1 | |
| Methylene Chloride SCHEMBL28121276 | 0.81 | TSHR (0.46) | IDO1AGXTLMNATSHRPTGS1 | |
| SCHEMBL5534909 | 0.80 | FFAR1 (0.48) | IDO1AGXTABCC4LMNAGAA | |
| SCHEMBL11506282 | 0.80 | LTA4H (0.52) | TSHRNAAAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788353-B1 | CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2022-05-18 | — | — | EP | claimed |
| EP-2137139-B1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | CLARIANT SPECIALTY FINE CHEM (FR) | 2014-09-10 | — | — | EP | claimed |
| US-8609882-B2 | Process for deacetalisation of α aminoacetals | CLARIANT SPECIALITY FINE CHEMICALS (FRANCE) (FR) | 2013-12-17 | — | — | US | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | claimed |
| US-20100137633-A1 | Process For Deacetalisation Of Alpha Aminoacetals | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-06-03 | — | — | US | claimed |
| CN-101679223-A | Deacetalization of alpha aminoacetals | CLARIANT SPECIALTY FINE CHEM | 2010-03-24 | — | — | CN | claimed |
| EP-2137139-A1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | Clariant Specialty Fine Chemicals (France) (FR) | 2009-12-30 | — | — | EP | claimed |
| WO-2008125486-A1 | PROCESS OF DEACETALISATION OF ALPHA AMINOACETALS | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2008-10-23 | — | — | WO | claimed |
| US-7432389-B2 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | claimed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| EP-1299352-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-04-09 | — | — | EP | claimed |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| EP-1265849-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2002-12-18 | — | — | EP | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | claimed |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2001070672-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | claimed |
| US-4826993-A | Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | claimed |
| US-4169939-A | PROCESSES FOR THE PRODUCTION OF 3',4'-DIDEOXYKANAMYCIN B | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | IDO1 1097/4885AGXT 147/4885GSTP1 1620/4885 |
| US-20100137633-A1 | Process For Deacetalisation Of Alpha Aminoacetals | ALDH7A1, AADAT, AASDHPPT | IDO1 126/4885AGXT 114/4885GSTP1 663/4885 |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BACE1 | IDO1 1663/4885AGXT 288/4885GSTP1 816/4885 |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, CHAT | IDO1 2174/4885AGXT 720/4885GSTP1 709/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | IDO1 2347/4885AGXT 465/4885GSTP1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.